Cancelled by the investigator Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)

Clinical Study of Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029816

Enrollment

Unknown

Registered

2020-02-14

Start date

2020-02-20

Completion date

Unknown

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Conventional treatment followed by Intravenous infusion of Cord Blood Mesenchymal Stem Cells preparations

Control group :Conventional treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia; 2. Voluntarily sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure; 2. Pregnant or lactating women; 3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.; 4. The investigator believes that the patient has other conditions that are not suitable for enrollment

Design outcomes

Secondary

Measure	Time frame
Time and rate of coronavirus become negative;Clearance rate and time of main symptoms (fever, fatigue, cough);Exacerbation (transfer to RICU) time;Routine blood test;Biochemical Indicators;Immune indices;	—

Primary

Measure	Time frame
Time to disease recovery;	—

Contacts

Public ContactChao Xu

Guangzhou reborn health management consultation co., LTD

164972769@qq.com+86 15018720816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026